Last updated on November 2018

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.


Brief description of study

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

Clinical Study Identifier: NCT02947165

Contact Investigators or Research Sites near you

Start Over

Novartis Investigative Site

Hong Kong, Hong Kong
5.77miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.